On 12 March 2011, an experimental artificial heart was implanted in 55-year-old Craig Lewis at The Texas Heart Institute in Houston by O. H. Frazier and William Cohn.
The device is a combination of two modified HeartMate II pumps that is currently undergoing bovine trials.

Frazier and Cohn are on the board of the BiVACOR company that develops an artificial heart.
BiVACOR has been tested as a replacement for a heart in a sheep.

So far, only one person has benefited from Frazier and Cohn's artificial heart.
Craig Lewis was suffering from amyloidosis in 2011 when his heart gave out and doctors pronounced that he had only 12 to 24 hours to live.
 After obtaining permission from his family, Frazier and Cohn replaced his heart with their device.
Lewis survived for another 5 weeks after the operation; he eventually succumbed to liver and kidney failure due to his amyloidosis, after which his family asked that his artificial heart be unplugged.
On 12 March 2011, an experimental artificial heart was implanted in 55-year-old Craig Lewis at The Texas Heart Institute in Houston by O. H. Frazier and William Cohn. The device is a combination of two modified HeartMate II pumps that is currently undergoing bovine trials.
Frazier and Cohn are on the board of the BiVACOR company that develops an artificial heart. BiVACOR has been tested as a replacement for a heart in a sheep.
So far, only one person has benefited from Frazier and Cohn's artificial heart. Craig Lewis was suffering from amyloidosis in 2011 when his heart gave out and doctors pronounced that he had only 12 to 24 hours to live.  After obtaining permission from his family, Frazier and Cohn replaced his heart with their device. Lewis survived for another 5 weeks after the operation; he eventually succumbed to liver and kidney failure due to his amyloidosis, after which his family asked that his artificial heart be unplugged.
Artificial heart